. Author manuscript; available in PMC: 2021 Dec 1.

Published in final edited form as: Biochim Biophys Acta Mol Cell Biol Lipids. 2021 Apr 20;1866(7):158939. doi: 10.1016/j.bbalip.2021.158939

Table 1.

Demographic characteristics of the cohort.

Variable	All	No/moderate ROP	Severe ROP	p (no/moderate vs severe ROP)
Infants, n	47	28	19
Samples, n	272	159	113
Boys, n (%)	28 (60)	15 (54)	13 (68)	0.309
BW, g [mean (SD)]	762 (222)	862 (217)	617 (133)	<0.001
BW SDS [mean (SD)]	−1.13 (1.45)	−0.96 (1.52)	−1.38 (1.34)	0.325
GA at birth, wks [mean (SD)]	25.0 (16)	25.7 (1.4)	24.0 (12)	<0.001
Receiving Smoflipid, n (%)	27 (57)	17 (61)	10 (53)	0.582

BW=birth weight; ROP = retinopathy of prematurity; no/moderate ROP = no ROP or ROP stages 1 or 2; severe ROP = ROP stage 3 and/or type 1 ROP; SD = standard deviation; SDS = standard deviation score.